Datamonitor Healthcare

Datamonitor Healthcare's Top Research Reports

Topic Clinical Trials Drug Pricing Sales Earnings Cell & Gene Therapy

HBW Insight

Sanofi's New Consumer Chief Identifies 'Untapped Potential' In Digital

Sanofi's recently-appointed Consumer Healthcare head Julie Van Ongevalle says she has identified "untapped potential" for the business to utilize "cutting edge digital platforms." Van Ongevalle revealed her early plans for Sanofi as it reported a drop in Q3 sales.

Topic Sales Earnings Digital Health

Scrip

Quick Listen: Scrip's Five Must-Know Things

Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.

Topic Sales Earnings

Scrip

Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs

Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.

Topic Coronavirus Sales Earnings Business Strategies

Scrip

Pfizer's Bourla Urges Patience As COVID-19 Vaccine Data Timeline Lags

Highly anticipated data from Pfizer's Phase III COVID-19 vaccine trial does not appear on track to be made publicly available in October as previously expected.

Topic Coronavirus Vaccines Sales Earnings

Scrip

Stockwatch: Pandemic And Biosimilar Effects Subordinate Early Third-Quarter Earnings Results

Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air

Topic Sales Earnings Coronavirus

Scrip

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.

Topic Coronavirus Vaccines Sales Earnings

Scrip

Gilead’s Major Challenge Is Sustainable Model For Remdesivir

With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.

Topic Coronavirus Sales Earnings Business Strategies

Scrip

Bayer Adds Up COVID-19 Pluses and Minuses In Q1

Bayer has beaten analyst forecasts for the first quarter but says the uncertainties brought about by the coronavirus pandemic prevent it from issuing financial guidance for the full year.

Topic Coronavirus Sales Earnings